Colchicine After Electrocardioversion for Atrial Fibrillation - The COLECTRO-AF Trial
Status: Recruiting
Location: See all (8) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY
The purpose of this study is to investigate whether a 3 month treatment course of low-dose Colchicine decreases the recurrence of Atrial fibrillation (AF) after electrocardioversion (ECV) in patients with AF.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Age \>18 years
• ECG-documented AF prior to ECV
• Successful ECV with conversion of AF to sinus rhythm with persistent sinus rhythm ≥30 minutes after ECV
• Ability to give written informed consent
Locations
Other Locations
Switzerland
University Hospital Basel
RECRUITING
Basel
University Hospital Bern
RECRUITING
Bern
Cantonal Hospital Baselland (KSBL)
RECRUITING
Bruderholz
Lausanne University Hospital
RECRUITING
Lausanne
Lucerne Cantonal Hospital
RECRUITING
Lucerne
Cantonal Hospital Olten
RECRUITING
Olten
Herzpraxis am Rhein
RECRUITING
Rheinfelden
Solothurner Spitäler AG
RECRUITING
Solothurn
Contact Information
Primary
Philipp Krisai, PD Dr. med.
Philipp.krisai@usb.ch
+41 61 265 25 25
Time Frame
Start Date: 2024-04-14
Estimated Completion Date: 2027-03
Participants
Target number of participants: 416
Treatments
Experimental: Experimental Group
Study participants in the active study arm will receive a daily oral dose of 0.5 mg Colchicine for 3 months without a loading dose. The dose is recommended to be taken in the morning. There is no deviation from the usual treatment intake.
Placebo_comparator: Control Group
Study participants in the placebo group will receive a matched placebo.
Related Therapeutic Areas
Sponsors
Leads: University Hospital, Basel, Switzerland
Collaborators: Swiss Heart Foundation, Foundation for Cardiovascular Research Basel, Fondation Machaon, Switzerland, Genf